Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Immune Design Corp (IMDZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7993
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:65
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design’s product candidates are used for the treatment of NY-ESO-1 tumor antigen, merkel cell carcinoma, non-hodgkin lymphoma, and others. It has collaboration with various pharmaceutical companies, to develop its product candidates through its GLAAS platform for the treatment of infectious disease, allergy and autoimmune diseases. Immune Design is headquartered in Seattle, Washington, the US.

Immune Design Corp (IMDZ) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immune Design Corp, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Immune Design Raises US$32.5 Million In Series C Financing 12
Immune Design Raises US$34 Million In Series B Financing 14
Partnerships 16
Immune Design Enters into Agreement with Gritstone Oncology 16
Immune Design Enters into Clinical Trial Collaboration with Genentech 17
Immune Design Enters into Clinical Collaboration Agreement with Merck 18
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 19
Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 20
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Immune Design 22
Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23
Immune Design Licensing Agreement with Oxford BioMedica 24
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 25
Equity Offering 26
Immune Design Prices USD80 Million in Public Offering of Shares 26
Immune Design Prices Public Offering of Shares for USD30 Million 28
Immune design Plans to Raise up to USD50 Million in Public offering of Shares 30
Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 31
Immune Design Raises USD60 Million in IPO 33
Immune Design Corp – Key Competitors 35
Immune Design Corp – Key Employees 36
Immune Design Corp – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 01, 2018: Immune Design reports second quarter 2018 financial results and provides corporate update 38
Mar 14, 2018: Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40
Nov 01, 2017: Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update 42
Aug 02, 2017: Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update 44
May 17, 2017: Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update 46
Mar 07, 2017: Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 48
Product News 50
09/25/2017: Immune Design Announces Upcoming Presentations at the SITC 32nd Annual Meeting 50
08/09/2018: Gritstone Oncology appoints experienced Financial Executive, Steve E. Krognes, to its Board of Directors 51
06/05/2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting 52
06/01/2017: Immune responses from early study of novel sarcoma vaccine 54
05/17/2017: New Clinical and Biomarker Data Validate Immune Design’s CMB305 Program 56
Clinical Trials 58
May 24, 2018: Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma 58
Mar 12, 2018: Immune Design Reports Data Update for Lead Immunotherapy Program: Improvement in Survival for CMB305 Monotherapy in Sarcoma 59
Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients 60
Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response 61
Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress 63
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Immune Design Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Immune Design Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immune Design Raises US$32.5 Million In Series C Financing 12
Immune Design Raises US$34 Million In Series B Financing 14
Immune Design Enters into Agreement with Gritstone Oncology 16
Immune Design Enters into Clinical Trial Collaboration with Genentech 17
Immune Design Enters into Clinical Collaboration Agreement with Merck 18
Immune Design Enters into Co-Development Agreement with Sanofi Pasteur 19
Immune Design Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute For Cancer Research 20
Sanofi Enters into Licensing Agreement with Immune Design 22
Immune Design Enters into Licensing Agreement with UNC Chapel Hill 23
Immune Design Licensing Agreement with Oxford BioMedica 24
Immune Design And Medicago Enter Into Licensing Agreement To Develop Influenza Vaccines 25
Immune Design Prices USD80 Million in Public Offering of Shares 26
Immune Design Prices Public Offering of Shares for USD30 Million 28
Immune design Plans to Raise up to USD50 Million in Public offering of Shares 30
Immune Design Completes Underwriters Partial Exercise of Over-Allotment of Public Offering of Shares 31
Immune Design Raises USD60 Million in IPO 33
Immune Design Corp, Key Competitors 35
Immune Design Corp, Key Employees 36
Immune Design Corp, Other Locations 37
Immune Design Corp, Subsidiaries 37

List of Figures
Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immune Design Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immune Design Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • British Arab Commercial Bank plc:企業の戦略的SWOT分析
    British Arab Commercial Bank plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • International Isotopes Inc (INIS)-医療機器分野:企業M&A・提携分析
    Summary International Isotopes Inc (INIS) is a provider of medical teletherapy products. The company offers radioisotope products for cancer therapy, nuclear medicine and industrial processes. It offers cobalt and radiochemical products and nuclear medicine calibration standards. INIS's cobalt and r …
  • EP Global Energy Ltd:電力:M&Aディール及び事業提携情報
    Summary EP Global Energy Ltd (EPGE) a subsidiary of Joannou & Paraskevaides (Overseas) Ltd. is a renewable energy service provider that offers services for development of wind, hybrid, solar power energy and conventional energy projects. The company offers renewable energy development, design, civil …
  • The Nature’s Bounty Co.:企業の戦略・SWOT・財務情報
    The Nature’s Bounty Co. - Strategy, SWOT and Corporate Finance Report Summary The Nature’s Bounty Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Acuity Brands Inc (AYI):電力:M&Aディール及び事業提携情報
    Summary Acuity Brands, Inc. (Acuity Brands) provides lighting and building management solutions and services. The company offers lighting solutions including devices such as luminaires, lighting controls, lighting components, power supplies, prismatic skylights, and integrated lighting systems. It a …
  • Interface Biologics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Interface Biologics Inc (IBI) is a medical device company that develops transformative biomedical polymer technologies. The company offers anti-thrombogenic and combination drug delivery devices. Its anti-thrombogenic additives reduce thrombosis in blood contacting medical devices and polyme …
  • Incanthera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Incanthera Ltd (Incanthera) is a drug development and targeted cancer medicines company that discovers and develops novel treatments for solid tumours. The company's pipeline drug candidates include ICT01-2588, a vascular disrupting agent, based on the tumor-blasting technology; ICT03 – Es5, …
  • H. Lee Moffitt Cancer Center & Research Institute Inc:医療機器:M&Aディール及び事業提携情報
    Summary H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider. It is engaged in the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services such a …
  • Reitmans (Canada) Limited (RET.A):企業の財務・戦略的SWOT分析
    Reitmans (Canada) Limited (RET.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • AusTex Oil Ltd:企業の戦略的SWOT分析
    AusTex Oil Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Inter RAO UES (IRAO):電力:M&Aディール及び事業提携情報
    Summary Inter RAO UES (Inter RAO) is a vertically integrated energy utility. It has presence in the energy value chain, including electricity generation, transmission, sales, trading and engineering. The company generates power in thermal, hydro, and co-generation plants; and supplies that energy on …
  • Genesis Energy Ltd:発電所・企業SWOT分析
    Genesis Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Capital Power Corporation (CPX)-エネルギー分野:企業M&A・提携分析
    Summary Capital Power Corporation (CPC) is a power producer that develops, acquires, operates, optimizes, and builds power generation facilities. It generates electricity from energy-efficient technology, lower-carbon fuel, and renewable sources using a range of energy sources. The company owns supe …
  • The Lubrizol Corporation-製薬・医療分野:企業M&A・提携分析
    Summary The Lubrizol Corporation (Lubrizol), a subsidiary of Berkshire Hathaway Inc., is a specialty chemical company that produces and supplies technologies to the global transportation, industrial, and consumer markets. Its products and services include engine additives, driveline additives, indus …
  • Phoenix Brands LLC:企業の戦略・SWOT・財務情報
    Phoenix Brands LLC - Strategy, SWOT and Corporate Finance Report Summary Phoenix Brands LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mahle GmbH:企業の戦略的SWOT分析
    Mahle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Tianjin Chase Sun Pharmaceutical Co Ltd (300026):企業の財務・戦略的SWOT分析
    Summary Tianjin Chase Sun Pharmaceutical Co Ltd (Chase Sun) is a medicine and health industry group. The company research, develops, produces, and markets various pharmaceutical products. It offers products such as Chinese herb preparations, Chinese medicinal granules, synthetic drugs, biotech drugs …
  • juwi AG:企業の戦略的SWOT分析
    juwi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Extendicare Inc.:企業の戦略・SWOT・財務分析
    Extendicare Inc. - Strategy, SWOT and Corporate Finance Report Summary Extendicare Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Illinois Municipal Electric Agency:企業の戦略的SWOT分析
    Illinois Municipal Electric Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆